Answers are grounded in this paper and cite their sources.
The MTD for E7107 using this schedule is 4.0 mg/m(2). Pharmacokinetics is dose-dependent and reproducible within patients. Pharmacodynamic analysis revealed dose-dependent reversible inhibition of pre-mRNA processing of target genes, confirming proof-of-principle activity of E7107.
No takes yet. Share an insight, caveat, or question.
Eskens et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: